For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | |||
|---|---|---|---|---|
| Research and development | 70,873 | |||
| General and administrative | 13,787 | |||
| Total operating expenses | 84,660 | |||
| Loss from operations | -84,660 | |||
| Interest income | 5,716 | |||
| Other income, net | 79 | |||
| Total other income | 5,795 | |||
| Net loss | -78,865 | |||
| Unrealized loss | -761 | |||
| Comprehensive loss | -79,626 | |||
| Basic EPS | -3,650 | |||
| Diluted EPS | -3,650 | |||
| Basic Average Shares | 21,607 | |||
| Diluted Average Shares | 21,607 | |||
Kailera Therapeutics, Inc. (KLRA)
Kailera Therapeutics, Inc. (KLRA)